Review
The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women

https://doi.org/10.1016/j.mayocp.2017.11.002Get rights and content
Under a Creative Commons license
open access

Abstract

The International Society for the Study of Women's Sexual Health process of care (POC) for management of hypoactive sexual desire disorder (HSDD) algorithm was developed to provide evidence-based guidelines for diagnosis and treatment of HSDD in women by health care professionals. Affecting 10% of adult females, HSDD is associated with negative emotional and psychological states and medical conditions including depression. The algorithm was developed using a modified Delphi method to reach consensus among the 17 international panelists representing multiple disciplines. The POC starts with the health care professional asking about sexual concerns, focusing on issues related to low sexual desire/interest. Diagnosis includes distinguishing between generalized acquired HSDD and other forms of low sexual interest. Biopsychosocial assessment of potentially modifiable factors facilitates initiation of treatment with education, modification of potentially modifiable factors, and, if needed, additional therapeutic intervention: sex therapy, central nervous system agents, and hormonal therapy, guided in part by menopausal status. Sex therapy includes behavior therapy, cognitive behavior therapy, and mindfulness. The only central nervous system agent currently approved by the US Food and Drug Administration (FDA) for HSDD is flibanserin in premenopausal women; use of flibanserin in postmenopausal women with HSDD is supported by data but is not FDA approved. Hormonal therapy includes off-label use of testosterone in postmenopausal women with HSDD, which is supported by data but not FDA approved. The POC incorporates monitoring the progress of therapy. In conclusion, the International Society for the Study of Women's Sexual Health POC for the management of women with HSDD provides a rational, evidence-based guideline for health care professionals to manage patients with appropriate assessments and individualized treatments.

Abbreviations and Acronyms

AE
adverse event
AI
aromatase inhibitor
CBT
cognitive behavior therapy
CHC
combined hormonal contraceptive
CNS
central nervous system
DHEA
dehydroepiandrosterone
DSDS
Decreased Sexual Desire Screener
HCP
health care professional
HSDD
hypoactive sexual desire disorder
ISSWSH
International Society for the Study of Women's Sexual Health
LoE
level of evidence
MetS
metabolic syndrome
PHQ
Patient Health Questionnaire
POC
process of care
SHBG
sex hormone–binding globulin

Cited by (0)

For editorial comment, 406; for related articles, see pages 429 and 458

Grant Support: Funding for this project was provided by the International Society for the Study of Women's Sexual Health from unrestricted educational grants from Valeant Pharmaceuticals International, Inc, AMAG Pharmaceuticals, Emotional Brain BV, and Palatin Technologies, Inc.

Potential Competing Interests: Dr Clayton has received grants from Auspex Pharmaceuticals, Inc, Forest Laboratories, Inc/Allergan, Genomind, Inc, Janssen Pharmaceuticals, Inc, Palatin Technologies, Inc, Sage Therapeutics, and Takeda Pharmaceutical Company Limited: has received personal fees for consulting services from Forest Laboratories, Inc/Allergan, Palatin Technologies, Inc, S1 Biopharma, Inc, Valeant Pharmaceuticals International, Inc, and Takeda Pharmaceutical Company Limited; and has shares/restricted stock units from Euthymics Bioscience, Inc, and S1 Biopharma, Inc.

Dr Goldstein is a consultant for AMG Pharmaceuticals, Atyu BioScience, Inc, Ipsen Biopharmaceuticals, Inc, Shionogi Inc, Strategic Science & Technologies, LLC, and Valeant Pharmaceuticals International, Inc: has received grants from Valeant Pharmaceuticals International, Inc, and Shionogi Inc; has received speaker's fees from AMAG Pharmaceuticals, ASCEND Therapeutics US, LLC, Cynosure, Inc, Nuelle, Inc, S1 Biopharma, Inc, Shionogi Inc, and Valeant Pharmaceuticals International, Inc; is on the advisory boards of Emotional Brain BV, Nuelle, Inc, The Female Health Company, and Valeant Pharmaceuticals International, Inc; and has participated in clinical trials supported by JoyLux, Inc, Palatin Technologies, Inc, and TherapeuticsMD, Inc.

Dr Kim is a consultant for Valeant Pharmaceuticals International, Inc and Sprout Pharmaceuticals, Inc, and has received research grants from Valeant Pharmaceuticals International, Inc, and Astellas Pharma US, Inc.

Dr Althof is a principal investigator for Palatin Technologies, Inc, and is a speaker for Valeant Pharmaceuticals International, Inc.

Dr Faubion is a consultant for Mithra Pharmaceuticals.

Ms Faught is a speaker for Actavis Pharma, Inc, and Valeant Pharmaceuticals International, Inc, and is on the advisory boards for Actavis, Palatin Technologies, Inc, and Valeant Pharmaceuticals International, Inc.

Dr Parish is a consultant for The Female Health Company; is on the advisory boards of Emotional Brain BV, Palatin Technologies, Inc, Pfizer, Inc, and Valeant Pharmaceuticals International, Inc; has received consulting fees/honoraria from Allergan, AMAG Pharmaceuticals, and Valeant Pharmaceuticals International, Inc; has received speaker's fees from Pfizer, Inc, and Valeant Pharmaceuticals International, Inc; and has received writing support from Pfizer, Inc.

Dr Simon is on the advisory boards of and is a consultant for AbbVie Inc, Allergan, AMAG Pharmaceuticals, Amgen Inc, Apotex Inc, ASCEND Therapeutics US, LLC, Azure Biotech, Inc, JDS Therapeutics, LLC, Merck & Co, Inc, Millendo Therapeutics, Inc, Noven Pharmaceuticals, Inc, Novo Nordisk A/S, Nuelle, Inc, Perrigo Company plc, Radius Health, Inc, Regeneron Pharmaceuticals, Roivant Sciences LTD, Sanofi, Sebela Pharmaceuticals Inc, Sermonix Pharmaceuticals, Shionogi Inc, Sprout Pharmaceuticals, inc, Symbiotec Pharmalab Pvt Ltd, TherapeuticsMD, Inc, Valeant Pharmaceuticals; is a speaker for Amgen, Eisai, Merck, Noven Pharmaceuticals, Novo Nordisk, Shionogi, and Valeant Pharmaceuticals International, Inc; has received research grants as principal investigator for AbbVie Inc, Actavis Pharma, Inc, Agile Therapeutics, Bayer Healthcare Pharmaceuticals LLC, GlaxoSmithKline plc, New England Research Institutes, Novo Nordisk A/S, Palatin Technologies, Inc, Symbio Research, TherapeuticsMD, Inc; and has stock (direct purchase) in Sermonix Pharmaceuticals.

Dr Davis is a consultant for and has received research grants from Lawley Pharmaceuticals Pty Ltd; has received speaker's fees from Pfizer, Inc, Abbott, and Besins Healthcare; and has received fees for development of educational presentations from Pfizer, Inc.

Dr Freeman is a consultant for Procter & Gamble and has received consulting fees from AMAG Pharmaceuticals; has received grants from Proctor & Gamble; and has received speaker's fees from Omnia-Prova Education Collaborative.

Dr Kingsberg is a consultant for SST Corporation, AMAG Pharmaceuticals, Emotional Brain BV, Endoceutics, Inc, Materna Medical, Valeant Pharmaceuticals International, Inc, Duchesnay USA, Shionogi Inc, TherapeuticsMD, Inc, Pfizer, Inc, Simbionix USA Corporation, and IVIX, Ltd; has received speaker's fees from Valeant Pharmaceuticals International, Inc, and AMAG Pharmaceuticals; has received fees for development of educational presentations from AMAG Pharmaceuticals, Endoceutics, Inc, Valeant Pharmaceuticals International, Inc, and Pfizer, Inc; has received speaking and consulting fees from Nuelle, Inc; and has stock options in Viveve, Inc.

Dr Kirana has received personal fees from The Menarini Group and Recordati SpA.

Dr Larkin is a speaker for Forefront and is on the advisory boards of Palatin Technologies, Inc, and Valeant Pharmaceuticals International, Inc.

Dr McCabe is on the advisory board of Actelion Pharmaceuticals Ltd.